Skip to main content
. 2014 Apr 25;3(2):e000588. doi: 10.1161/JAHA.113.000588

Figure 2.

Figure 2.

Primary study end point. There was no significant increase in the conversion rate of the placebo arm (Fisher's exact test, placebo 5/294=1.7% vs verapamil 2/297=0.7%, P=0.28). Superiority margin for the primary end point was set as low as 5.0 percentage points. Since the 95% CI for the difference in effect of the 2 regimens overlaps zero not crossing the superiority margin, the strategy of preventive verapamil use may not be considered superior to the policy of ad hoc administration (difference in conversion rates 1.0%, 95% CI −1.1% to 3.3%).